News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alnylam Pharmaceuticals (ALNY) Announces Tuschl II Key Patent Claims Upheld in Invalidation Trial in Japan



10/9/2012 10:40:51 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the Japanese Patent Office upheld key claims in the Tuschl II patent (JP4095895) in an invalidation trial held in Japan. The invalidation request was made by Bio Think-Tank, a Japanese company.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES